BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32583034)

  • 21. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
    J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck.
    Wu MP; Sethi RKV; Emerick KS
    Laryngoscope; 2020 Jan; 130(1):108-114. PubMed ID: 30843617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.
    Brantsch KD; Meisner C; Schönfisch B; Trilling B; Wehner-Caroli J; Röcken M; Breuninger H
    Lancet Oncol; 2008 Aug; 9(8):713-20. PubMed ID: 18617440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma.
    Krediet JT; Beyer M; Lenz K; Ulrich C; Lange-Asschenfeldt B; Stockfleth E; Terhorst D
    Br J Dermatol; 2015 Apr; 172(4):1029-36. PubMed ID: 25362868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
    Hanania HL; Lewis DJ
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
    [No Abstract]   [Full Text] [Related]  

  • 27. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma.
    Tejera-Vaquerizo A; García-Doval I; Llombart B; Cañueto J; Martorell-Calatayud A; Descalzo-Gallego MA; Sanmartín O
    J Dermatol; 2018 Jul; 45(7):781-790. PubMed ID: 29701281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updates on Merkel Cell Carcinoma.
    Emge DA; Cardones AR
    Dermatol Clin; 2019 Oct; 37(4):489-503. PubMed ID: 31466589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 31. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
    Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
    Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
    Gambichler T; Hessam S; Lüttringhaus T; Boms S
    Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
    Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
    J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 35. The Role of Total Parotidectomy for Metastatic Cutaneous Squamous Cell Carcinoma and Malignant Melanoma.
    Thom JJ; Moore EJ; Price DL; Kasperbauer JL; Starkman SJ; Olsen KD
    JAMA Otolaryngol Head Neck Surg; 2014 Jun; 140(6):548-54. PubMed ID: 24722863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Merkel cell carcinoma].
    Drusio C; Becker JC; Schadendorf D; Ugurel S
    Hautarzt; 2019 Mar; 70(3):215-227. PubMed ID: 30701288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
    Burton KA; Ashack KA; Khachemoune A
    Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
    Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP
    Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.